Inflation Rate in China decreased to 0 percent in July from 0.10 percent in June of 2025. This dataset provides - China Inflation Rate - actual values, historical data, forecast, chart, statistics, economic calendar and news.

Dior web scraped data

  About the website

The luxury fashion industry in the Asia Pacific region, and in particular in China, is a rapidly expanding sector. As the middle class grows in wealth, there is an increasing demand for high-end goods from prestigious brands such as Christian Dior. The sector has been greatly influenced by technological innovations, the most notable of which is ecommerce. In recent years, there has been a significant shift in consumer behavior with… See the full description on the dataset page: https://huggingface.co/datasets/DBQ/Dior.Product.prices.China.

Hermes web scraped data

  About the website

The luxury goods industry in the Asia Pacific, particularly in China, is experiencing significant growth driven by rising wealth and changing consumer preferences. Hermes, a high-end luxury brand, is a notable player within this affluent sector. This industrys success is tied to the robust ecommerce landscape in China, characterized by innovative digital platforms with extensive customer reach. The dataset examined contains… See the full description on the dataset page: https://huggingface.co/datasets/DBQ/Hermes.Product.prices.China.

Note: Updates to this data product are discontinued. The China agricultural and economic database is a collection of agricultural-related data from official statistical publications of the People's Republic of China. Analysts and policy professionals around the world need information about the rapidly changing Chinese economy, but statistics are often published only in China and sometimes only in Chinese-language publications. This product assembles a wide variety of data items covering agricultural production, inputs, prices, food consumption, output of industrial products relevant to the agricultural sector, and macroeconomic data.This record was taken from the USDA Enterprise Data Inventory that feeds into the https://data.gov catalog. Data for this record includes the following resources: Query tool For complete information, please visit https://data.gov.

Balenciaga web scraped data

  About the website

The fashion industry in the Asia Pacific region, particularly in China, is a hotbed of activity. It is one of the most lucrative markets in the world, spurred by a fast-growing middle class with an increased appetite for luxury products. The Chinese market, especially, plays host to many high-end, luxury fashion brands like Balenciaga. A significant transition has been noted in the mode of shopping, with a sharp turn towards… See the full description on the dataset page: https://huggingface.co/datasets/DBQ/Balenciaga.Product.prices.China.

Burberry web scraped data

  About the website

The luxury fashion industry in the Asia Pacific region, particularly in China, has seen a significant shift towards digitalization. Online shopping, fuelled by the growth of Ecommerce, has become a major sales channel for high-end labels like Burberry. This growth in online sales has outpaced that of the offline sector, making e-commerce a key driver for the luxury fashion sector. Chinese consumption of luxury goods is turning… See the full description on the dataset page: https://huggingface.co/datasets/DBQ/Burberry.Product.prices.China.

Consumer Price Index CPI in China increased to 103.20 points in April from 103.10 points in March of 2025. This dataset provides - China Consumer Price Index (CPI) - actual values, historical data, forecast, chart, statistics, economic calendar and news.

Background: Pembrolizumab is a potentially valuable treatment. However, patients, doctors, and healthcare decision-makers are uncertain about its cost-effectiveness and an appropriate pricing for this new therapy. This study aims to appraise the cost-effectiveness of pembrolizumab as a first-line treatment for advanced biliary tract cancer (BTC) patients in China and the United States (US).Methods: A Markov model was constructed from the perspectives of healthcare systems in both China and the US for pharmacoeconomic evaluation. Patient baseline characteristics and key clinical data were sourced from the KEYNOTE-966 trial (ClinicalTrials.gov, NCT04003636). Costs and utilities were collected from drug cost websites and published literature. Cumulative costs (in USD), life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were measured and compared. Price simulations were conducted under given willingness-to-pay (WTP) thresholds to provide pricing scheme references. The model’s robustness was analyzed through one-way sensitivity analysis and probabilistic sensitivity analysis.Results: Basic data analysis illustrates that pembrolizumab ($2662.41/100 mg) in combination with chemotherapy regimen was not cost-effective relative to chemotherapy regimens at the WTP threshold of $38,201.19 in China, and the additional cost relative to chemotherapy regimens was $77,114.94 (ICER $556,689.47/QALY) while increasing 0.14 QALYs. Pembrolizumab ($54.71/1 mg) also increased efficacy by 0.14 QALYs in the US, but remained also not cost-effective at the US WTP threshold of $229,044, and the total cost increased by $160,425.24 (ICER $1,109,462.92/QALY).Conclusion: Compared with chemotherapy, pembrolizumab plus chemotherapy reduces the disease of burden. However, at its current price, it may not be a cost-effective treatment for advanced BTC in both China and the US. This study can aid decision-makers in making optimal choices.

About This Dataset: Copper Prices and Market Trends

    This dataset provides **insights into copper prices**, including current rates, historical trends, and key factors affecting price fluctuations. Copper is essential in **construction**, **electronics**, and **transportation** industries. Investors, traders, and analysts use accurate copper price data to guide decisions related to **trading**, **futures**, and **commodity investments**.

    ### **Key Features of the Dataset**

    #### **Live Market Data and Updates**
    Stay updated with the latest **copper price per pound** in USD. This data is sourced from exchanges like the **London Metal Exchange (LME)** and **COMEX**. Price fluctuations result from **global supply-demand shifts**, currency changes, and geopolitical factors.

    #### **Interactive Copper Price Charts**
    Explore **dynamic charts** showcasing real-time and historical price movements. These compare copper with **gold**, **silver**, and **aluminium**, offering insights into **market trends** and inter-metal correlations.

    ### **Factors Driving Copper Prices**

    #### **1. Supply and Demand Dynamics**
    Global copper supply is driven by mining activities in regions like **Peru**, **China**, and the **United States**. Disruptions in production or policy changes can cause **supply shocks**. On the demand side, **industrial growth** in countries like **India** and **China** sustains demand for copper.

    #### **2. Economic and Industry Trends**
    Copper prices often reflect **economic trends**. The push for **renewable energy** and **electric vehicles** has boosted long-term demand. Conversely, economic downturns and **inflation** can reduce demand, lowering prices.

    #### **3. Impact of Currency and Trade Policies**
    As a globally traded commodity, copper prices are influenced by **currency fluctuations** and **tariff policies**. A strong **US dollar** typically suppresses copper prices by increasing costs for international buyers. Trade tensions can also disrupt **commodity markets**.

    ### **Applications and Benefits**

    This dataset supports **commodity investors**, **traders**, and **industry professionals**:

    - **Investors** forecast price trends and manage **investment risks**. 
    - **Analysts** perform **market research** using price data to assess **copper futures**. 
    - **Manufacturers** optimize supply chains and **cost forecasts**.

    Explore more about copper investments on **Money Metals**:

    - [**Buy Copper Products**](https://www.moneymetals.com/buy/copper) 
    - [**95% Copper Pennies (Pre-1983)**](https://www.moneymetals.com/pre-1983-95-percent-copper-pennies/4) 
    - [**Copper Buffalo Rounds**](https://www.moneymetals.com/copper-buffalo-round-1-avdp-oz-999-pure-copper/297)

    ### **Copper Price Comparisons with Other Metals**

    Copper prices often correlate with those of **industrial** and **precious metals**:

    - **Gold** and **silver** are sensitive to **inflation** and currency shifts. 
    - **Iron ore** and **aluminium** reflect changes in **global demand** within construction and manufacturing sectors.

    These correlations help traders develop **hedging strategies** and **investment models**.

    ### **Data Variables and Availability**

    Key metrics include:

    - **Copper Price Per Pound:** The current market price in USD. 
    - **Copper Futures Price:** Data from **COMEX** futures contracts. 
    - **Historical Price Trends:** Long-term movements, updated regularly. 

    Data is available in **CSV** and **JSON** formats, enabling integration with analytical tools and platforms.

    ### **Conclusion**

    Copper price data is crucial for **monitoring global commodity markets**. From **mining** to **investment strategies**, copper impacts industries worldwide. Reliable data supports **risk management**, **planning**, and **economic forecasting**.

    For more tools and data, visit the **Money Metals** [Copper Prices Page](https://www.moneymetals.com/copper-prices).

Background: The DESTINY-Breast03 clinical trial demonstrated that trastuzumab deruxtecan (T-DXd) outperformed trastuzumab emtansine (T-DM1) in progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). Considering the excessive cost of antibody-drug conjugates, the clinical value of T-DXd must be assessed by both its efficacy and cost. We compared the cost-effectiveness of T-DXd and T-DM1 for patients with HER2-positive mBC pretreated with anti-HER2 antibodies and a taxane from the perspectives of the United States (US) and China.Methods: A comprehensive Markov model based on the DESTINY-Breast03 phase III randomized clinical trial was used to compared the cost and effectiveness of T-DXd and T-DM1 for HER2-positive mBC. Data on direct medical cost and utilities were collected from published literatures. The recorded data included the costs, quality-adjusted life-year (QALY), incremental cost-effectiveness ratio (ICER) and incremental net-health benefit (INHB). Sensitivity analysis was conducted to measure the potential uncertainty due to parameter variability. Additional subgroup cost-effectiveness analysis was performed.Results: Treatment of HER2-positive mBC with T-DXd gained 0.73 QALYs compared with T-DM1 strategy. The incremental cost was $59,942 in the US, with an ICER of $ 82,112/QALY and an INHB of 0.33 QALYs, respectively. In China, the incremental cost of T-DXd versus T-DM1 was $222,680, with an ICER of $305,041/QALY and a negative INHB of -5.18 QALYs. At willingness-to-pay (WTP) threshold of $150,000/QALY in the US and $37,653/QALY in China, the probability of T-DXd as the dominant option was 77.5 and 0.1%, respectively. The unit price of T-DXd greatly influenced the results according to one-way sensitivity analysis. To meet the 50% or 90% chance of being cost-effective, the estimated cost of T-DXd would need to be less than $17.24/mg and $12.06/mg in China, respectively.Conclusion: T-DXd is more cost-effective than T-DM1 for patients with HER2-positive mBC in the US, but not in China at current drug prices.

242 United States import shipment records of Automatic pick and place from China Taiwan with prices, volume & current Buyer’s suppliers relationships based on actual United States import trade database.

1934 United States import shipment records of Head and neck from Cn China with prices, volume & current Buyer’s suppliers relationships based on actual United States import trade database.

The steel rebar prices in the United States for Q3 2024 reached 860 USD/MT in September. The region experienced notable price drops amid declining demand and excess supply. Prices consistently trended downward, with a minor decrease at the end of the quarter. This persistent bearish sentiment highlighted ongoing challenges in stabilizing the market as excess supply continued to weigh heavily on pricing dynamics.

Gasoline Prices in China remained unchanged at 0.85 USD/Liter in July. This dataset provides the latest reported value for - China Gasoline Prices - plus previous releases, historical high and low, short-term forecast and long-term prediction, economic calendar, survey consensus and news.

Background and ObjectiveUnresectable hepatocellular carcinoma (uHCC) is the main histological subtype of liver cancer and causes a great disease burden in China. We aimed to evaluate the cost-effectiveness of five first-line systemic treatments newly approved in the Chinese market for the treatment of uHCC, namely, sorafenib, lenvatinib, donafenib, sintilimab plus bevacizumab (D + A), and atezolizumab plus bevacizumab (T + A) from the perspective of China's healthcare system, to provide a basis for decision-making.MethodsWe constructed a network meta-analysis of 4 clinical trials and used fractional polynomial models to indirectly compare the effectiveness of treatments. The partitioned survival model was used for cost-effectiveness analysis. Primary model outcomes included the costs in US dollars and health outcomes in quality-adjusted life-years (QALYs) and the incremental cost-effectiveness ratio (ICER) under a willingness-to-pay threshold of $33,521 (3 times the per capita gross domestic product in China) per QALY. We performed deterministic and probabilistic sensitivity analyses to investigate the robustness. To test the effect of active treatment duration on the conclusions, we performed a scenario analysis.ResultsCompared with sorafenib, lenvatinib, donafenib, D + A, and T + A regimens, it yielded an increase of 0.25, 0.30, 0.95, and 1.46 life-years, respectively. Correspondingly, these four therapies yielded an additional 0.16, 0.19, 0.51, and 0.86 QALYs and all four ICERs, $40,667.92/QALY gained, $27,630.63/QALY gained, $51,877.36/QALY gained, and $130,508.44/QALY gained, were higher than $33,521 except for donafenib. T + A was the most effective treatment and donafenib was the most economical option. Sensitivity and scenario analysis results showed that the base-case analysis was highly reliable.ConclusionAlthough combination therapy could greatly improve patients with uHCC survival benefits, under the current WTP, donafenib is still the most economical option.

The price of ethylamine in the United States for Q4 2023 reached 2753 USD/MT in December and the price trend for ethylamine in China reached 2013 USD/MT in December 2023.

Steel fell to 3,112 CNY/T on August 22, 2025, down 0.32% from the previous day. Over the past month, Steel's price has fallen 2.99%, but it is still 3.87% higher than a year ago, according to trading on a contract for difference (CFD) that tracks the benchmark market for this commodity. Steel - values, historical data, forecasts and news - updated on August of 2025.

8 United States import shipment records of Plastics and others from Cn China with prices, volume & current Buyer’s suppliers relationships based on actual United States import trade database.

2 United States import shipment records of Machine tool and accessories from China Taiwan with prices, volume & current Buyer’s suppliers relationships based on actual United States import trade database.

Soybeans rose to 1,035.54 USd/Bu on August 22, 2025, up 0.10% from the previous day. Over the past month, Soybeans's price has risen 2.96%, and is up 8.75% compared to the same time last year, according to trading on a contract for difference (CFD) that tracks the benchmark market for this commodity. Soybeans - values, historical data, forecasts and news - updated on August of 2025.